Metastatic Therapy-Duration Spend Forecast

A subscription actuarial model that converts stage-specific cancer survival statistics into forecasts of how long metastatic patients stay on therapy, so payers and PBMs can budget oncology drug spend that legacy models calibrated on shorter-survival baselines systematically underestimate.